Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases

Agarwala SS (2004) Relevance and necessity of studies on second-line chemotherapy in melanoma. Onkologie 27:527–528

Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, Paradise C, Kunkel L, Rosenberg SA (1999) High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17:2105–2116

Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Restifo NP, Haworth LR, Levy C, Mauroukakis SA, Nichol G, Yellin MJ, Rosenberg SA (2005) Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 23:6043–6053

Beck KE, Blansfield JA, Tran KQ, Feldan AL, Hughes MS, Royal RE, Kammula US, Topalian SL, Sherry RM, Kleiner D, Quezado M, Lowy I, Yellin M, Rosenberg SA, Yang JC (2006) Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 24:2283–2289

Chen B, Phillips J, Greenbaum M, Klitzing D, Cardarelli PM, Korman A (2007) Efficacy of anti-CTLA-4 antibody in the Sa1 N tumor model when combined with dexamethasone (abstract 2202). In: Presented at the AACR Annual Meeting, 14–28 April 2007, Los Angeles, CA, USA

ClinicalTrials.gov. A single arm study of ipilimumab monotherapy in patients with previously treated unresectable stage III or IV melanoma. http://clinicaltrials.gov/ct/show/NCT00289627

ClinicalTrials.gov. A companion study for patients enrolled in prior/parent ipilimumab studies. http://clinicaltrials.gov/show/NCT00162123

Fischkoff SA, Hersh E, Weber J, Powderly J, Khan K, Pavlick A, Samlowski W, O’Day S, Nichol G, Yellin M (2005) Durable responses and long-term progression-free survival observed in a phase II study of MDX-010 alone or in combination with dacarbazine (DTIC) in metastatic melanoma (abstract 7525). J Clin Oncol 23(suppl)

Hamid O, Urba WJ, Yellin M, Nichol GM, Weber J, Hersh EM, Tchekmedyian S, Hodi FS, Weber R, O’Day S (2007) Ipilimumab (MDX-010) in patients with stage III/IV melanoma: kinetics and duration of response. Eur J Cancer Suppl 5:396

Hersh EM, O’Day SJ, Powderly J, Khan KD, Pavlick AC, Cranmer L, Samlowski WE, Nichol GM, Yellin MJ, Fischkoff SA, Weber JS (2008) Disease control and long-term survival in chemotherapy-naive patients with advanced melanoma treated with ipilimumab with or without dacarbazine. J Clin Oncol (submitted)

Hodi FS, The Global Ipilimumab Melanoma Study Group (2008) Novel efficacy criteria for antitumor activity to immunotherapy using the example of ipilimumab, an anti-CTLA-4 monoclonal antibody (abstract 3008). J Clin Oncol 26(suppl)

Lin R, Yellin MJ, Lowy I, Safferman A, Chin K, Ibrahim R (2008) An analysis of the effectiveness of specific guidelines for the management of ipilimumab-mediated diarrhea/colitis: prevention of gastrointestinal perforation and/or colectomy (abstract 9063). J Clin Oncol 26(suppl)

Maker AV, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Hughes M, Yellin MJ, Haworth LR, Levy C, Allen T, Mavroukakis SA, Attia P, Rosenberg SA (2006) Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunother 29:455–463

O’Day S, Boasberg P (2006) Management of metastatic melanoma 2005. Surg Oncol Clin N Am 15:419–437

O’Day SJ, Hamid O, Urba WJ (2007) Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer 110:2614–2627

Saenger Y, Wolchok J (2008) The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases. Cancer Immun 8:1

Sasse AD, Sasse EC, Clark LGO, Ulloa L, Clark OAC (2007) Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma. Cochrane Database of Systematic Reviews 2007, Iss 1. Art No: CD005413. doi: 10.1002/14651858.CD005413.pub2

Tarhini AA, Kirkwood JM, Gooding WE, Cai C, Agarwala SS (2007) Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy. J Clin Oncol 25:3802–3807

Weber J (2007) Anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse effects. Oncologist 12:864–872

Weber JS, Hersh EM, Yellin M, Nichol GM, Urba W, Powderly JD, O’Day SJ (2007) The efficacy and safety of ipilimumab (MDX-010) in patients with unresectable stage III or stage IV malignant melanoma [abstract 8523]. J Clin Oncol 25(suppl)

Weber JS, Targan S, Scotland R, Snively J, Garcia M, Yellin M, Fischkoff S, Nichol G (2006) Phase II trial of extended dose anti-CTLA-4 antibody ipilimumab (formerly MDX-010) with a multi-peptide vaccine for resected stages IIIC and IV melanoma (abstract 2510). J Clin Oncol 18(suppl)

Wolchok JD, The Global Ipilimumab Melanoma Study Group (2008) Antitumor response and new lesions in advanced melanoma patients on ipilimumab treatment (abstract 3020). J Clin Oncol 26(suppl)